Novartis, Novo Nordisk drug failures will likely ‘pop a hole in the balloon’ of the field
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Novartis, Novo Nordisk drug failures will likely ‘pop a hole in the balloon’ of the field" is generating significant coverage in the Business category, with 1 articles from 1 distinct sources tracked by PULSE so far.
Outlets currently covering the story include medscape.com. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 46d ago.
Quick answers
Why is "Novartis, Novo Nordisk drug failures will likely ‘pop a hole in the balloon’ of " trending?
Because 1 independent news sources published 1 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (1)
- Sep 11, 2026 This Week in Cardiology Podcast medscape.com · 48d ago
Topics
Related trends
Novartis CEO keeps faith in Avidity deal despite taking $1.9B hit from del-desiran fail
7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Novo Nordisk and Eli Lilly Just Got Some Fantastic News
Novo Nordisk and Eli Lilly receive positive news amid ongoing developments in drug discovery and aging research.
Probing the many benefits of GLP-1 receptor agonists
6 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Novartis to License Drug From China’s Abogen in Up to $7.8 Billion Deal
Novartis strikes a massive licensing agreement worth up to $7.8 billion with China-based biotech firm Abogen.
Novartis takes rights to Abogen’s mRNA T cell engager for $575M upfront
Novartis secures the rights to Abogen’s mRNA T cell engager in a massive $575 million upfront transaction.
Novartis pens $7.8B deal for Abogen's in vivo autoimmune T-cell engager
Novartis has agreed to a massive new mRNA drug deal with Chinese startup Abogen worth up to $7.8 billion.